In April 2026, EPA released a proposal that, if finalized, would begin the process to potentially regulate the presence of pharmaceuticals in drinking water, by designating them as “Candidate Contaminants.” This proposal is likely to be of significant interest to pharmaceutical manufacturers, given that it entails EPA evaluating, in detail
Continue Reading EPA Begins Process to Regulate Pharmaceuticals in Drinking WaterPharmaceuticals
The EPR Obligations of the New Urban Wastewater Treatment Directive: Key Questions and Next Steps for Member States
By Zoé Bertrand & Cándido García Molyneux on
Posted in Uncategorized
The European Union has recently published a new (recast) Urban Wastewater Treatment Directive (“UWWTD”) in the EU’s official journal. The UWWTD imposes important new Extended Producer Responsibility (“EPR”) obligations that will have a significant financial and administrative impact on companies marketing human medicines and cosmetic products in the…
Continue Reading The EPR Obligations of the New Urban Wastewater Treatment Directive: Key Questions and Next Steps for Member StatesEPA Publishes Final Hazardous Waste Pharmaceuticals Rule, With Significant Implications for Pharmaceuticals and Product Recalls
By Thomas Brugato on
Posted in Environmental Enforcement
EPA published today in the Federal Register its final rule governing hazardous waste pharmaceuticals. This rule adopts a novel scheme under the Resource Conservation and Recovery Act (“RCRA”) for the management of hazardous waste pharmaceuticals that are discarded by healthcare facilities or managed by “reverse” distributors. It also applies to other types of products such as e-cigarettes, liquid nicotine, and dietary supplements.
Continue Reading EPA Publishes Final Hazardous Waste Pharmaceuticals Rule, With Significant Implications for Pharmaceuticals and Product Recalls